### PERSPECTIVE

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>897</td>
<td>Estrogen Receptors in Colorectal Cancer: Goalkeepers, Strikers, or Bystanders?</td>
<td>Johan Hartman and Jan-Åke Gustafsson</td>
</tr>
</tbody>
</table>

**See article p. 910**

### REVIEW

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>900</td>
<td>Chemoprevention of Head and Neck Cancer with Green Tea Polyphenols</td>
<td>Joseph W. Kim, A.R.M. Ruhul Amin, and Dong M. Shin</td>
</tr>
</tbody>
</table>

### RESEARCH ARTICLES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>910</td>
<td>Estrogen Stimulates the Expression of Mismatch Repair Gene hMLH1 in Colonic Epithelial Cells</td>
<td>Peng Jin, Xiao-juan Lu, Jian-qiu Sheng, Lei Fu, Xiao-ming Meng, Xin Wang, Tai-ping Shi, Shi-rong Li, and Jianyu Rao</td>
</tr>
<tr>
<td></td>
<td>Validation of a Novel Statistical Model for Assessing the Synergy of Combined-Agent Cancer Chemoprevention</td>
<td>Junya Fujimoto, Maiying Kong, J. Jack Lee, Waun Ki Hong, and Reuben Lotan</td>
</tr>
<tr>
<td>994</td>
<td>Preclinical Colorectal Cancer Chemopreventive Efficacy and p53-Modulating Activity of 3',4',5'-Trimethoxyflavonol, a Quercetin Analogue</td>
<td>Lynne M. Howells, Robert G. Britton, Marco Mazzolletti, Peter Greaves, Massimo Broggini, Karen Brown, William P. Steward, Andreas J. Gescher, and Stewart Sale</td>
</tr>
<tr>
<td>1015</td>
<td>Dual Inhibition of Both the Epidermal Growth Factor Receptor and erbB2 Effectively Inhibits the Promotion of Skin Tumors during Two-Stage Carcinogenesis</td>
<td>Kaoru Kiguichi, Takuya Kitamura, Tricia Moore, Mohammad Rumi, Hsiang-Chun Chang, Devon Treece, Lynnsie Ruffino, Kevin Connolly, and John DiGiovanni</td>
</tr>
</tbody>
</table>

**New Role of (−)-Epicatechin in Enhancing the Induction of Growth Inhibition and Apoptosis in Human Lung Cancer Cells by Curcumin**

Achinto Saha, Takashi Kuzuhara, Noriko Echigo, Masami Suganuma, and Hirota Fujiki

**Novel Application of Proton Pump Inhibitor for the Prevention of Colitis-Induced Colorectal Carcinogenesis beyond Acid Suppression**

Yoon Jae Kim, Jeong Sang Lee, Kyung Sook Hong, Jun Won Chung, Ju Hyun Kim, and Ki Baik Hahn

**1,4-Phenylenedi(Methylene) Selenocyanate, but Not Selenomethionine, Inhibits Androgen Receptor and Akt Signaling in Human Prostate Cancer Cells**

Nicole D. Facompre, Karam El-Bayoumy, Yuan-Wan Sun, John T. Pinto, and Raghu Sinha

**Green Tea Polyphenols and Metabolites in Prostatectomy Tissue: Implications for Cancer Prevention**

Piwen Wang, William J. Aronson, Min Huang, Yanjun Zhang, Ru-Po Lee, David Heber, and Susanne M. Henning

**Proteomic Profiling of Potential Molecular Targets of Methyl-Selenium Compounds in the Transgenic Adenocarcinoma of Mouse Prostate Model**

Jinhui Zhang, Lei Wang, Lorraine R. Anderson, Bruce Wuthuhn, Yanji Xu, and Junxuan Liu

**No Association between Endogenous Retinoic Acid and Human Papillomavirus Clearance or Incident Cervical Lesions in Brazilian Women**

Erin M. Siegel, Jason L. Salemi, Neal E. Craft, Luisa L. Villa, Alex S. Ferenczy, Eduardo L. Franco, and Anna R. Giuliano

**Cryptothanshinone Inhibits Cancer Cell Proliferation by Suppressing Mammalian Target of Rapamycin–Mediated Cyclin D1 Expression and Rb Phosphorylation**

Wenxing Chen, Yan Luo, Lei Liu, Hongyu Zhou, Baoshan Xu, Xiaozhen Han, Tao Shen, Zhijun Liu, Yin Lu, and Shile Huang
1026  

Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy  
Min Yi, Kelly K. Hunt, Banu K. Arun, Isabelle Bedrosian, Angelica Gutierrez Barrera, Kim-Anh Do, Henry M. Kuerer, Gildy V. Babiera, Elizabeth A. Mittendorf, Kaylene Ready, Jennifer Litton, and Funda Meric-Bernstam

1035  

Oral Selenium Supplementation Has No Effect on Prostate-Specific Antigen Velocity in Men Undergoing Active Surveillance for Localized Prostate Cancer  
M. Suzanne Stratton, Amit M. Algotar, James Ranger-Moore, Steven P. Stratton, Elizabeth H. Slate, Chiu-Hsieh Hsu, Patricia A. Thompson, Larry C. Clark, and Frederick R. Ahmann

MEETING REPORT

1044  

Conference Report: Eighth Annual ACCR International Conference on Frontiers in Cancer Prevention Research  
Abenaa M. Brewster, Sherri L. Patterson, Michele R. Forman, Chanita Hughes-Halbert, Paul J. Limburg, Frank G. Ondrey, Electra D. Paskett, David W. Wetter, and Ernest T. Hawk

ABOUT THE COVER

The cover image of four contour plots reflects a novel statistical methodology for assessing the chemopreventive synergy of combined agents (epigenetic modulators in this case). Standard statistics for two-drug combinations are limited for addressing complex dose-response patterns of chemopreventive combinations, which can involve nonmonotonic, or nonlinear, relationships with a plateau effect or U-shaped curve. The Emax and recently developed semiparametric statistical models can address such complexities. Each contour plot shows the growth-inhibition effects of a demethylating agent (AZA) plus a histone deacetylase inhibitor (SAHA) at different doses and/or schedules in tumorigenic human bronchial epithelial cells without serum. AZA was added to cells at an early (Early AZA) and late (Late AZA) time point, whereas SAHA was added only at the late time point. The x axis (AZA) and y axis (SAHA) show doses in μmol/L. The complex dose-response relationships included only an additive (white area) or antagonistic (Ant., pink area) relationship of late AZA plus SAHA with no early AZA (top-left panel) and increasingly synergistic effects (Syn.) when adding low doses of late AZA to SAHA plus increasing doses of early AZA (light-blue areas in the top-right, lower-left, and lower-right panels). Numbers adjacent to the contour lines indicate beyond-additive growth inhibition, i.e., differences between the observed and predicted growth inhibition. The graph data were generated via the Emax and Loewe-additivity models (predicted additive growth inhibition) and the semiparametric model (beyond-additive growth inhibition and confidence bands). These results are part of a comprehensive set of experiments and analyses that validated this novel statistical approach for assessing the synergy of combined chemopreventive drugs. See article by Fujimoto et al. (beginning on page 917) for more information.
Cancer Prevention Research

3 (8)


Updated version Access the most recent version of this article at: http://cancerpreventionresearch.aacrjournals.org/content/3/8

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.